CEBP  Translational Cancer Medicine 2008: Cancer Clinical Trials and Personalized Medicine
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jerónimo, C.
Right arrow Articles by Sidransky, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jerónimo, C.
Right arrow Articles by Sidransky, D.
Cancer Epidemiology Biomarkers & Prevention Vol. 11, 445-450, May 2002
© 2002 American Association for Cancer Research

I105V Polymorphism and Promoter Methylation of the GSTP1 Gene in Prostate Adenocarcinoma1

Carmen Jerónimo2, Graça Varzim, Rui Henrique, Jorge Oliveira, Maria José Bento, Cristina Silva, Carlos Lopes and David Sidransky

Departments of Pathology [C. J., G. V., R. H., C. S., C. L.], Genetics [C. J.], Urology [J. O.], and Epidemiology [M. J. B.], Portuguese Institute of Oncology, 4200–072 Porto, Portugal; and Department of Otolaryngology-Head and Neck Surgery, Head and Neck Cancer Research Division, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205 [D. S.]

The GSTP1 gene encodes for an enzyme, glutathione S-transferase {pi} (GST{pi}),involved in detoxification of carcinogens. An aminoacid substitution (I105V) in GSTP1 produces a variant enzyme with lower activity and less capability of effective detoxification. This variant GSTP*B allele has been associated with a propensity to develop several neoplasms. Because GSTP1 promoter hypermethylation and inactivation of GST{pi} expression is a frequent alteration in prostate carcinoma, we hypothesized that this somatic epigenetic modification could obviate any reduced enzyme activity caused by the germ-line polymorphism. We tested for the GSTP1 genotype in a population of prostate cancer patients, and in a control group composed of patients with benign prostatic hyperplasia (BPH) and healthy blood donors. Tissue samples from the 105 prostate cancer cases (105 adenocarcinomas and 34 prostatic intraepithelial neoplasia lesions), and from 43 BPH patients were tested for GSTP1 hypermethylation by methylation-specific PCR. GST{pi} protein expression was assessed by immunohistochemistry. No significant effect on prostate cancer risk was detectable for GSTP1 genotype compared with the control population (odds ratio, 1.02; 95% confidence interval, 0.59–1.75). Moreover, no association was found between this genotype and tumor or BPH methylation status. Patients with unmethylated carcinomas did not disclose significant differences in genotypic distribution compared with the control population. In adenocarcinoma, a strong association (P < 0.00001) between GSTP1 promoter hypermethylation and loss of GST{pi} expression was observed; however, this trend was not retained in prostatic intraepithelial neoplasia or BPH lesions. Although the GSTP1 polymorphism is not associated with altered susceptibility to prostate cancer, somatic promoter hypermethylation is an effective, but not the only, cause of decreased GST{pi} function.




This article has been cited by other articles:


Home page
Mol Cancer ResHome page
R. Henrique, C. Jeronimo, M. R. Teixeira, M. O. Hoque, A. L. Carvalho, I. Pais, F. R. Ribeiro, J. Oliveira, C. Lopes, and D. Sidransky
Epigenetic Heterogeneity of High-Grade Prostatic Intraepithelial Neoplasia: Clues for Clonal Progression in Prostate Carcinogenesis
Mol. Cancer Res., January 1, 2006; 4(1): 1 - 8.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
G. S. Palapattu, S. Sutcliffe, P. J. Bastian, E. A. Platz, A. M. De Marzo, W. B. Isaacs, and W. G. Nelson
Prostate carcinogenesis and inflammation: emerging insights
Carcinogenesis, July 1, 2005; 26(7): 1170 - 1181.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
Q. K.Y. Chan, U.-S. Khoo, H. Y.S. Ngan, C.-Q. Yang, W.-C. Xue, K. Y.K. Chan, P.-M. Chiu, P. P.C. Ip, and A. N.Y. Cheung
Single Nucleotide Polymorphism of Pi-Class Glutathione S-Transferase and Susceptibility to Endometrial Carcinoma
Clin. Cancer Res., April 15, 2005; 11(8): 2981 - 2985.
[Abstract] [Full Text] [PDF]


Home page
JNCI J Natl Cancer InstHome page
L.-C. Li, P. R. Carroll, and R. Dahiya
Epigenetic Changes in Prostate Cancer: Implication for Diagnosis and Treatment
J Natl Cancer Inst, January 19, 2005; 97(2): 103 - 115.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
C. Ntais, A. Polycarpou, and J. P.A. Ioannidis
Association of GSTM1, GSTT1, and GSTP1 Gene Polymorphisms with the Risk of Prostate Cancer: A Meta-analysis
Cancer Epidemiol. Biomarkers Prev., January 1, 2005; 14(1): 176 - 181.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Pathol.Home page
C Jeronimo, R Henrique, J Oliveira, F Lobo, I Pais, M R Teixeira, and C Lopes
Aberrant cellular retinol binding protein 1 (CRBP1) gene expression and promoter methylation in prostate cancer
J. Clin. Pathol., August 1, 2004; 57(8): 872 - 876.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
J. V. Tricoli, M. Schoenfeldt, and B. A. Conley
Detection of Prostate Cancer and Predicting Progression: Current and Future Diagnostic Markers
Clin. Cancer Res., June 15, 2004; 10(12): 3943 - 3953.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
C. Jeronimo, R. Henrique, M. O. Hoque, F. R. Ribeiro, J. Oliveira, D. Fonseca, M. R. Teixeira, C. Lopes, and D. Sidransky
Quantitative RAR{beta}2 Hypermethylation: A Promising Prostate Cancer Marker
Clin. Cancer Res., June 15, 2004; 10(12): 4010 - 4014.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
Y. Zhu, M. R. Spitz, C. I. Amos, J. Lin, M. B. Schabath, and X. Wu
An Evolutionary Perspective on Single-Nucleotide Polymorphism Screening in Molecular Cancer Epidemiology
Cancer Res., March 15, 2004; 64(6): 2251 - 2257.
[Abstract] [Full Text] [PDF]


Home page
JNCI J Natl Cancer InstHome page
L. Kopelovich, J. A. Crowell, and J. R. Fay
The Epigenome as a Target for Cancer Chemoprevention
J Natl Cancer Inst, December 3, 2003; 95(23): 1747 - 1757.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
M. Nakayama, C. J. Bennett, J. L. Hicks, J. I. Epstein, E. A. Platz, W. G. Nelson, and A. M. De Marzo
Hypermethylation of the Human Glutathione S-Transferase-{pi} Gene (GSTP1) CpG Island Is Present in a Subset of Proliferative Inflammatory Atrophy Lesions but Not in Normal or Hyperplastic Epithelium of the Prostate: A Detailed Study Using Laser-Capture Microdissection
Am. J. Pathol., September 1, 2003; 163(3): 923 - 933.
[Abstract] [Full Text] [PDF]


Home page
Ann. N. Y. Acad. Sci.Home page
M. VERMA, B. K. DUNN, S. ROSS, P. JAIN, W. WANG, R. HAYES, and A. UMAR
Early Detection and Risk Assessment Proceedings and Recommendations from the Workshop on Epigenetics in Cancer Prevention
Ann. N.Y. Acad. Sci., March 1, 2003; 983(1): 298 - 319.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation
Copyright © 2002 by the American Association for Cancer Research.